Compare Cassava Sciences Inc (FLNA) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kroger Co — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Kroger Co trades at $61.26 (market cap $34.99B). The key difference: Kroger Co is far larger — about 888.1× Cassava Sciences Inc's market cap, and Kroger Co pays a 2.63% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Kroger Co for 108 Days on average.
| FLNA | KR | |
|---|---|---|
Market Cap | $39.40M | $34.99B |
Volume | 759,018 | 8,938,607 |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $75.60 |
52-Week Low | $0.68 | $55.53 |
Typical Hold Time | 37 Days | 108 Days |
Enterprise Value | -$43.28M | $56.41B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Kroger (KR) trades at $59.25, up 1.44% with a bullish technical signal. The stock shows strong fundamentals with $147.12B revenue and $2.67B net income for 2025, supported by positive cash flow trends. Recent earnings beat expectations in two of the last three quarters, while analysts maintain a Moderate Buy consensus with a $70.62 price target. The company continues digital growth initiatives and maintains dividend payments.
Kroger presents a value opportunity with low P/S ratio (0.25) and consistent profitability, though near-term risks include integration challenges from acquisitions and softer sales guidance. The stock's current price near support at $58 offers potential upside to analyst targets, balanced by competitive pressures in the grocery sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
